DK2118128T3 - Fusionsproteiner omfattende tumorrejektionantigenerne NY-ESO-1 og LAGE-1 - Google Patents

Fusionsproteiner omfattende tumorrejektionantigenerne NY-ESO-1 og LAGE-1

Info

Publication number
DK2118128T3
DK2118128T3 DK08727588.9T DK08727588T DK2118128T3 DK 2118128 T3 DK2118128 T3 DK 2118128T3 DK 08727588 T DK08727588 T DK 08727588T DK 2118128 T3 DK2118128 T3 DK 2118128T3
Authority
DK
Denmark
Prior art keywords
lage
eso
fusion proteins
tumor rejection
rejection antigens
Prior art date
Application number
DK08727588.9T
Other languages
English (en)
Inventor
Normand Blais
Martine Boyer
Vincent Brichard
Jamila Louahed
Denis Martin
Remi M Palmantier
Clement Rioux
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0700759A external-priority patent/GB0700759D0/en
Priority claimed from GB0701262A external-priority patent/GB0701262D0/en
Priority claimed from GB0709707A external-priority patent/GB0709707D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK2118128T3 publication Critical patent/DK2118128T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK08727588.9T 2007-01-15 2008-01-11 Fusionsproteiner omfattende tumorrejektionantigenerne NY-ESO-1 og LAGE-1 DK2118128T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0700759A GB0700759D0 (en) 2007-01-15 2007-01-15 Novel fusion protein
GB0701262A GB0701262D0 (en) 2007-01-23 2007-01-23 Vaccine
US91484807P 2007-04-30 2007-04-30
US91492507P 2007-04-30 2007-04-30
GB0709707A GB0709707D0 (en) 2007-05-21 2007-05-21 Novel fusion protein
PCT/US2008/050879 WO2008089074A2 (en) 2007-01-15 2008-01-11 Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1

Publications (1)

Publication Number Publication Date
DK2118128T3 true DK2118128T3 (da) 2013-02-18

Family

ID=41111108

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08727588.9T DK2118128T3 (da) 2007-01-15 2008-01-11 Fusionsproteiner omfattende tumorrejektionantigenerne NY-ESO-1 og LAGE-1

Country Status (15)

Country Link
EP (1) EP2118128B1 (da)
JP (1) JP2010532656A (da)
KR (1) KR20090122426A (da)
BR (1) BRPI0806501A2 (da)
CA (1) CA2674458A1 (da)
DK (1) DK2118128T3 (da)
EA (1) EA016818B1 (da)
ES (1) ES2398492T3 (da)
HR (1) HRP20130022T1 (da)
MX (1) MX2009007572A (da)
PE (1) PE20081687A1 (da)
PL (1) PL2118128T3 (da)
SI (1) SI2118128T1 (da)
TW (1) TW200902049A (da)
WO (1) WO2008089074A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008308474A (ja) * 2007-06-18 2008-12-25 Nitto Denko Corp 抗原ペプチド製剤の調製方法
MX2011009597A (es) 2009-03-17 2012-05-29 Glaxosmithkline Biolog Sa Deteccion mejorada de la expresion del gen.
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
JP6041314B2 (ja) * 2011-08-31 2016-12-07 国立大学法人三重大学 がん治療用ワクチン製剤
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
CN109893648A (zh) * 2013-06-28 2019-06-18 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
EP3053592A4 (en) 2013-10-01 2017-09-06 Mie University T cell-inducing vaccine containing interepitope sequence promoting antigen presentation
BR112017013574A2 (pt) 2014-12-23 2018-03-06 Verdon Daniel conjugados de aminoácido e peptídeo e usos dos mesmos
SG11201807036QA (en) 2016-02-26 2018-09-27 Auckland Uniservices Ltd Amino acid and peptide conjugates and conjugation process
CA3119865A1 (en) * 2018-11-23 2020-05-28 Strike Pharma Ab Bi-specific conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06205672A (ja) * 1992-03-19 1994-07-26 Nippon Zeon Co Ltd 日本脳炎ウイルス及びｂ型肝炎ウイルスの表面抗原タンパク質の抗原部位を持つキメラタンパク質の製造法、およびそれに用いる組み換えバキュロウイルス
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
ATE507295T1 (de) * 2000-03-30 2011-05-15 Dendreon Corp Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
AU2004314347B2 (en) * 2003-12-24 2011-05-19 Aduro Biotech, Inc. Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
SG159554A1 (en) * 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
EP2021017A2 (en) * 2006-05-26 2009-02-11 GlaxoSmithKline Biologicals S.A. Method
CA2674552A1 (en) * 2007-01-15 2008-07-24 Glaxosmithkline Biologicals S.A. Vaccine

Also Published As

Publication number Publication date
PL2118128T3 (pl) 2013-03-29
PE20081687A1 (es) 2008-12-25
EA016818B1 (ru) 2012-07-30
WO2008089074A3 (en) 2008-12-31
BRPI0806501A2 (pt) 2014-04-22
TW200902049A (en) 2009-01-16
ES2398492T3 (es) 2013-03-19
HRP20130022T1 (hr) 2013-02-28
CA2674458A1 (en) 2008-07-24
EP2118128A2 (en) 2009-11-18
EP2118128B1 (en) 2012-11-07
MX2009007572A (es) 2009-10-13
EA200900738A1 (ru) 2010-02-26
WO2008089074A9 (en) 2012-07-12
SI2118128T1 (sl) 2013-02-28
KR20090122426A (ko) 2009-11-30
WO2008089074A2 (en) 2008-07-24
JP2010532656A (ja) 2010-10-14

Similar Documents

Publication Publication Date Title
DK2118128T3 (da) Fusionsproteiner omfattende tumorrejektionantigenerne NY-ESO-1 og LAGE-1
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK1844074T3 (da) Humane antistoffer og proteiner
DK2222706T3 (da) Antibodies against human nkg2d and uses thereof
ZA201002160B (en) Human gm-csf antigen binding proteins
DK2176296T3 (da) Anti-CD79B-antistoffer og immunkonjugater og anvendelsesfremgangsmåder.
NO20080692L (no) SP35 antistoffer og anvendelse derav
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
DK2068887T3 (da) SP35-antistoffer og anvendelser heraf
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
DK3002298T3 (da) Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf
BRPI1012340A8 (pt) proteínas de ligação específica e usos das mesmas
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
DK1924600T3 (da) Identifikation af tumor-associerede antigener for diagnose og terapi
DK2152748T3 (da) Anti-Notch1-NRR-antistoffer og fremgangsmåder til anvendelse deraf
BRPI0807480A2 (pt) Ligando, imunoglobulina g, composição e proteína de fusão
DK3118221T3 (da) Proteiner
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
DK1996625T3 (da) Anti-Tat226 antistoffer og immunkonjugater
DK3321287T3 (da) Fusionsproteiner og kombinationsvacciner
DK3168229T3 (da) Fremstilling af proteiner og polypeptider.
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
BR112014019459A2 (pt) proteínas de ligação à cdim e usos das mesmas
BRPI0814127A2 (pt) Polipeptídeos imunegênicos e anticorpos monoclonais
PL2144924T3 (pl) Szczepionka z białkiem fuzyjnym